Anixa Biosciences Set to Participate in Water Tower Research Insights Conference on April 14, 2026 Anixa Biosciences, a biotech firm focused on cancer treatment, will present at the Water Tower Research Insights Conference on April 14, 2026.

Anixa Biosciences Set to Participate in Water Tower Research Insights Conference on April 14, 2026 #United_States #Anixa_Biosciences #San_Jose #Cancer_Vaccine #lira-cel

Infinitopes Raises $35 Million to Propel Cancer Vaccine Development and Transform Patient Care Infinitopes has successfully raised a total of $35.1 million in seed funding, aimed at advancing its promising cancer vaccine ITOP1 towards clinical trials, targeting oesophageal cancer.

Infinitopes Raises $35 Million to Propel Cancer Vaccine Development and Transform Patient Care #United_Kingdom #Oxford #Cancer_Vaccine #Infinitopes #ITOP1

NEUVOGEN Unveils Innovative Cancer Vaccine Data at AACR Annual Meeting NEUVOGEN presented groundbreaking findings on its new cancer vaccine NGEN-143 at the AACR Annual Meeting, showcasing its potential against non-small cell lung cancer.

NEUVOGEN Unveils Innovative Cancer Vaccine Data at AACR Annual Meeting #USA #San_Diego #Cancer_Vaccine #NEUVOGEN #NGEN-143

NEUVOGEN Expands Its Scientific Advisory Board with Leading Experts in Cancer Research NEUVOGEN Inc. has announced the addition of Nobel laureate Dr. James P. Allison and Dr. Padmanee Sharma to its Scientific Advisory Board, enhancing its cancer vaccine expertise.

NEUVOGEN Expands Its Scientific Advisory Board with Leading Experts in Cancer Research #USA #San_Diego #Immunotherapy #Cancer_Vaccine #NEUVOGEN

Anixa Biosciences Advances with Ovarian Cancer Vaccine Patent Allowance from USPTO Anixa Biosciences, Inc. has received a Notice of Allowance for its ovarian cancer vaccine patent, marking a critical step in cancer prevention and treatment.

Anixa Biosciences Advances with Ovarian Cancer Vaccine Patent Allowance from USPTO #United_States #Anixa_Biosciences #San_Jose #Cancer_Vaccine #Ovarian_Cancer

Esphera SynBio Secures $2M Seed Funding to Enhance Cancer Vaccines Through Synthetic Biology Esphera SynBio has raised $2 million in seed funding aiming to advance its nanomedicine vaccine platform for cancer and infectious diseases.

Esphera SynBio Secures $2M Seed Funding to Enhance Cancer Vaccines Through Synthetic Biology #Canada #Cancer_Vaccine #Esphera_SynBio #nanomedicine #Hamilton,_Ontario

BioVaxys Unveils Promising Findings on DPX Immune Platform at Cancer Vaccine Summit BioVaxys Technology Corp. presented promising new data regarding its DPX immune educating platform, highlighting its effectiveness in cancer vaccines.

BioVaxys Unveils Promising Findings on DPX Immune Platform at Cancer Vaccine Summit #Canada #Vancouver #BioVaxys #DPX_Technology #Cancer_Vaccine